Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
David Resinger
since
auto-detected in 11 stories
32 days ago
page 1 of 1